36 C
Vientiane
Sunday, April 27, 2025
spot_img
Home Blog Page 109

Hurom’s E50ST Slow Juicer Wins 2025 Red Dot Design Award

SEOUL, South Korea, April 16, 2025 /PRNewswire/ — Hurom’s newest juicer, the E50ST Slow Juicer, has been awarded a 2025 Red Dot Design Award, a globally prestigious honor recognizing outstanding achievements in product design.

▲ Hurom E50ST Slow Juicer
▲ Hurom E50ST Slow Juicer

Recognized as one of the world’s top three design competitions—alongside Germany’s iF Design Award and the IDEA Design Award in the U.S.—the Red Dot Design Award has been hosted by Germany’s Design Zentrum Nordrhein Westfalen since 1955. Winning entries are selected each year through a rigorous evaluation process by leading international design experts.

Hurom’s E50ST impressed judges with its innovation, functionality, emotional appeal, eco-consciousness, and durability, winning the main prize in the Product Design category.

As part of Hurom’s latest “Pure Line” series, the E50ST integrates next-generation juicing technology with a precision fine-mesh filter to deliver smooth, clear, and nutrient-rich juice with exceptional performance.

Launched this year, the E50ST stands out for its sleek, approachable design—a minimalist body, softly curved lines, and a refined material finish that encourages consumer connection. By highlighting the natural matte texture of the materials and avoiding additional surface treatments, the design achieves a cohesive, sculptural aesthetic. The ventilation grille at the base of the unit adds both form and function—deliberately patterned for optimal airflow to dissipate motor heat while enhancing the visual appeal with its subtle detailing.

Since launching its first product in 2008, Hurom has been recognized for its world-class product design, winning multiple accolades at the world’s top three design awards, including four Red Dot Design Awards, four iF Design Awards, and three IDEA Design Awards.

In addition, the Hurom E50ST was awarded the Kitchen Innovation Award 2025 this past February in Germany. Presented annually at Ambiente—the world’s largest consumer goods trade fair held in Frankfurt—the award recognizes products that combine innovation with a deep understanding of consumer needs. What distinguishes this honor is its dual evaluation process, combining expert jury assessment with consumer voting for added credibility. The E50ST earned high praise in four core categories: functionality, ease of use, product excellence, and overall quality.

Hurom CEO Jae-won Kim shared, “We’re honored that our new E50ST Slow Juicer has received back-to-back recognition from such prestigious global awards,” adding “As a pioneer in slow juicing, Hurom remains committed to delivering innovative, design-forward products that help people live healthier lives worldwide.”

NORTH AMERICA’S 50 BEST BARS UNVEILS INAUGURAL LIST OF BARS RANKED 51st TO 100th FOR 2025

LONDON, April 16, 2025 /PRNewswire/ — North America’s 50 Best Bars 2025, sponsored by Perrier, has revealed the inaugural 51-100 list. This extended list is the result of the votes cast by the voting Academy, which is comprised of more than 300 independent cocktail experts, renowned bartenders, educators and drinks writers from across the region.

North America’s 50 Best Bars, sponsored by Perrier, announces the inaugural extended 51-100 list for 2025
North America’s 50 Best Bars, sponsored by Perrier, announces the inaugural extended 51-100 list for 2025

The 51-100 List in Numbers

  • The 51-100 list includes bars spanning 23 destinations across North America
  • The US leads the list with 29 bars represented, from cities across the country including New York, Los Angeles and Chicago as well as Albuquerque, Boston, Houston, Miami, New Orleans, Phoenix, and more
  • Canada boasts 15 institutions on the list, hailing from Vancouver, Toronto, Montreal, Calgary and Victoria
  • Mexico City, Oaxaca and Playa del Carmen have a combined total of 5 bars featured

The 51-100 list celebrates the rich and diverse cocktail cultures across the region in the lead-up to the unveiling of the 1-50 list on April 29 in Vancouver, Canada.

Emma Sleight, Head of Content for North America’s 50 Best Bars, says “In sharing the 51-100 list, we recognize the hard work and dedication of even more of the hospitality and drinks community and shine a spotlight on the development of exceptional drinks culture across the region.”

Topping the 51-100 list is Library Bar in Toronto at No.51. Other Canadian bars include Missy’s at No.52 from Calgary and Bar Bisou Bisou at No.75 from Montreal.

Bars from across the US include destinations like Austin’s Nickel City at No.70, Albuquerque’s Happy Accidents at No.88, Honolulu’s Bar Leather Apron at No.73, Houston’s Bandista at No.59 and Boston’s Equal Measure at No.81. Bars in Seattle on the list include Roquette at No.72, The Doctor’s Office at No.76 and Canon at No.79.

Five bars from Mexico are featured: Sabina Sabe (No.54), Brujas (No.65), Zapote Bar (No.74), Ticuchi (No.82) and Casa Prunes (No.94).

The full list can be viewed here.

The 1-50 list of North America’s 50 Best Bars 2025, sponsored by Perrier, will be revealed at a live awards ceremony in Vancouver on April 29 in collaboration with host destination partner, Destination Vancouver. The countdown of the list will be broadcast live to a global audience who are unable to attend in person, through the 50 Best Bars TV channel on YouTube.

Media center access:
https://mediacentre.theworlds50best.com/

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan[1]) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study[2].

IPAX-Linz is a single-arm Phase 2 investigator-initiated trial (IIT). IPAX-Linz evaluates the safety, tolerability and preliminary efficacy of TLX101 therapy, in combination with external beam radiation therapy (EBRT). The target patient population is patients at first or second recurrence with high-grade gliomas (HGG), including glioblastoma.

Treatment with TLX101 was well tolerated with no serious adverse events reported. IPAX-Linz demonstrated encouraging preliminary efficacy data, indicating a median overall survival (OS) of 12.4 months from the initiation of treatment with TLX101, or 32.2 months from initial diagnosis[3]. This is consistent with the positive efficacy signal generated in the IPAX-1 study in patients at first recurrence, with only one prior resection and treatment with standard chemoradiotherapy. IPAX-1 reported a median OS of 13 months from the initiation of treatment with TLX101, or 23 months from initial diagnosis[4]. In comparison, recurrent glioblastoma patients treated with EBRT alone have a reported median survival of 9.9 months from treatment[5].

Eight patients were included in the study with adaptive dosing of intravenous TLX101 up to administered activity of 4 GBq before, and up to 2 GBq after, second line EBRT, administered in sequential injections. Inclusion criteria comprised patients with glioblastoma with current evidence of first or second recurrence after standard radiochemotherapy, at least six months since end of first line EBRT, and molecular imaging with Telix’s investigational PET[6] agent for glioma, TLX101-CDx (Pixclara®[7]18F-floretyrosine, or 18F-FET), indicating pathologically increased amino acid uptake. Surgery for relapsed tumors was allowed. Of the eight IPAX-Linz patients, five had MGMT unmethylated tumors[8], typically associated with especially poor prognosis.

Professor Josef Pichler, Kepler University Hospital, Austria, Principal Investigator in the IPAX-Linz, IPAX-1, and IPAX-2 studies, commented, “These preliminary results in relapsed patients showed that TLX101 treatment was very well tolerated, with no serious adverse events, at a higher dose than in previous studies. Early efficacy from IPAX-1 was corroborated, despite the poor prognostic parameters with MGMT unmethylated tumors and multiple relapses before commencing experimental therapy in this IPAX-Linz study. TLX101 continues to show significant potential to improve outcomes for patients living with high-grade glioma. These results also potentially support higher therapeutic doses in subsequent prospective controlled studies.”

Dr. David Cade, Chief Medical Officer at Telix, said, “These are encouraging results, offering new options for patients with historically poor outcomes. We are grateful to Dr. Pichler and his team for building on the IPAX-1 study in a more advanced and complex study cohort that is also representative of a real-world patient population.”

Preliminary results from IPAX-Linz will be presented by Dr. Pichler at the Nuclear Medicine and Neurooncology (NMN) Symposium taking place in Vienna, Austria from 9 – 10 May 2025. Visit the event website for further information: https://www.nmn-society.org/

TLX101 Development Program and Registration-Enabling Study Update

Telix continues to investigate TLX101 in front-line and recurrent settings. IPAX-2, a Phase 1/2 study in front-line glioblastoma in combination with standard of care and using TLX101-CDx as a companion diagnostic, continues to recruit patients.

Telix has submitted for ethics approval a registration-enabling study of TLX101 in recurrent glioblastoma. Subject to approval this will enable patient enrolment to commence at Australian sites in H2 2025, ahead of international expansion. Following the successful pre-IND[9] meeting with the U.S. Food and Drug Administration (FDA) in Q4 2024, the Company is also on track to submit an IND application in H1 2025, with the goal of commencing the study at U.S. sites in H2 2025.

About TLX101

TLX101 (131I-iodofalan or 131I-IPA) is a systemically administered targeted radiation therapy that targets L-type amino acid transporter 1 (LAT1), which is typically over-expressed in glioblastoma. TLX101 therapy utilizes a small molecule approach due to the need to cross the blood brain barrier, the normal protective barrier that prevents many potential drug candidates entering the brain. TLX101 has received orphan drug designation in the U.S. and Europe for the treatment of glioma. TLX101 and TLX101-CDx have not received a marketing authorization in any jurisdiction.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedInX and Facebook.

Telix Investor Relations
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country.

[1] 131I-iodofalan is the International Nonproprietary Name (INN) assigned to TLX101 by the World Health Organization. TLX101 is also known as 4-L-[131I] iodo-phenylalanine, or 131I-IPA.

[2] Telix ASX disclosure 21 September 2022. Pichler et al. Neurooncol Adv. 2024. ClinicalTrials.gov ID: NCT03849105.

[3] Primary endpoints were safety and tolerability; secondary endpoints comprised progression-free survival and overall survival.

[4] Collation of available data, not from head-to-head data. Cross-trial results should be interpreted with caution and may require further follow-up or validation.

[5] Kulinich et al. Acta Neurochir (Wien). 2021.

[6] Positron emission tomography.

[7] Brand name subject to final regulatory approval.

[8] MGMT (O6-methylguanine-DNA methyltransferase) is an enzyme that repairs DNA damage caused by chemotherapy, leading to resistance.

[9] Investigational New Drug.

 

Verkada Expands Asia Pacific Leadership Team to Continue Driving Regional Growth

Steve Bray Joins Verkada as Regional Vice President, Australia and New Zealand; Blake Day joins Verkada as Head of ASEAN

SAN MATEO, Calif., April 16, 2025 /PRNewswire/ — Verkada, a pioneer in cloud-based physical security, today announced two key additions to its Asia-Pacific leadership team: Steve Bray joins as Regional Vice President for Australia and New Zealand, where he will lead go-to-market strategy and operations from Verkada’s Sydney office; and Blake Day joins as Head of ASEAN, where he will oversee regional growth and execution from Verkada’s ASEAN headquarters in Singapore.

Blake Day, Head of ASEAN, at Verkada
Blake Day, Head of ASEAN, at Verkada

“Demand for Verkada’s cloud-based security solutions across Australia, New Zealand, and South East Asia continues to grow,” said Eric Salava, Chief Revenue Officer at Verkada. “The addition of proven leaders like Steve and Blake to our team underscores our deep commitment to these fast-growing markets and the opportunity ahead of our team as we make even more communities across the world safer.”

Bray brings more than two decades of enterprise technology and SaaS expertise across Australia and New Zealand. With leadership experience from Cloudflare, Zendesk, Salesforce, and Oracle, Bray’s deep relationships across the Australia and New Zealand IT channel and strong track record of scaling go-to-market operations will play a key role in continuing to accelerate Verkada’s growth in the region.

“Verkada sets a new standard for simplicity and scalability in physical security,” said Steve Bray, Regional Vice President, Australia and New Zealand, at Verkada. “As organizations across Australia and New Zealand look for modern, future-proofed solutions to help them keep their people and places safe, Verkada is perfectly positioned to support them and continue growing our presence in the region.”

Day joins Verkada from Workday, where he spent more than eight years leading high-performing teams and consistently surpassing sales targets across roles in both the U.S. and Singapore. Over the past three years, he led Workday’s Singapore business, helping to expand the company’s presence and deepen its customer base across the ASEAN region.

Bray and Day join Verkada’s deep bench of leaders in the Japan and Asia Pacific region at an exciting time for the company. Verkada’s customer base in the region has grown by 60% over the past year, and the company recently expanded its offices in Sydney and Singapore to support its growing team. Verkada also announced new partnerships with leading integrators and channel partners across the region, including Bluechip Infotech, Focus Digital Security Solutions, Field Solutions Holdings, LG CNS, and Takachiho Koheki.

About Verkada
Designed with simplicity in mind, Verkada’s six product lines — video security cameras, access control, environmental sensors, alarms, workplace, and intercoms — provide unparalleled building security through an integrated, cloud-based software platform. Over 30,000 organizations across 93 countries worldwide, including 91 of the Fortune 500, trust Verkada as their physical security layer for easier management, intelligent control, and scalable deployments. For more information, please visit www.verkada.com.

Steve Bray, Regional Vice President, Australia and New Zealand, at Verkada
Steve Bray, Regional Vice President, Australia and New Zealand, at Verkada

 

DreamWorks Animation’s Kung Fu Panda Joins Forces with Ragnarok Online in New Collaboration

BUENA PARK, Calif., April 16, 2025 /PRNewswire/ — Gravity Interactive, Inc., in collaboration with Universal Products & Experiences, announced today that it has launched a DreamWorks Animation Kung Fu Panda integration in their celebrated world of Ragnarok Online. In this collaboration, from April 15 to May 13, 2025, Kung Fu Panda‘s main character Po, Zhen and Shifu will appear in Prontera as event NPCs. 

The four-week event introduces meticulously crafted character-inspired accessories including specialty headwear, unique garments, and lovable floppy dolls featuring fan favorites inspired by Kung Fu Panda. Each accessory maintains character authenticity while fitting naturally within Ragnarok Online’s art style.

In addition to cosmetic offerings, the event features:

  • Exclusive Training Quests: Players can train alongside Po and Master Shifu in specially designed-gameplay scenarios
  • Reward Exchange System: Special collaboration coins earned through gameplay can be traded with Zhen for specific in-game rewards including two power-enhancing food items and two collectible dolls
  • Limited-Edition Collaboration Card: A unique buff-enhancing card available exclusively during this event

This limited time event arrives as Ragnarok Online continues to demonstrate remarkable longevity in the competitive MMORPG landscape, now in its third decade of continuous operation. The game maintains its player base through strategic collaborations and content refreshes while preserving the core gameplay mechanics that originally captivated millions worldwide.

Players can find complete event details through the official Ragnarok Online website, as well as on Facebook, Twitter (X), Steam beginning April 15, 2025.

About Ragnarok Online

First launched in 2002, Ragnarok Online has established itself as one of gaming’s most resilient MMORPGs, blending 2D character sprites with 3D environments in a world inspired by Norse mythology. The game offers players unparalleled freedom to explore, battle, socialize, and craft their unique identities across a vast, interconnected world.

About Gravity Interactive, Inc.

Gravity Interactive, Inc., founded in California in 2003, has been at the forefront of bringing Gravity games to North American audiences and players worldwide. As a wholly-owned subsidiary of Gravity Co., Ltd., the company continues to support and expand the Ragnarok Online experience across multiple territories.

About DreamWorks Animation’s KUNG FU PANDA

Inspired by traditional martial arts and set in ancient China, Kung Fu Panda tells the epic tale of wide-eyed Po, whose love of kung fu is matched only by an insatiable appetite. The Academy Award®-nominated 2008 inaugural chapter became DreamWorks’ highest-grossing original animated film. With the release of Kung Fu Panda 4, the film franchise has earned more than $2 billion at the global box office. With its massive fan base, the franchise has expanded to a cross-category consumer products program, video games, an Emmy Award-winning television series and global Universal Destinations & Resorts theme-park attractions.

About Universal Products & Experiences

Universal Products & Experiences (UP&E) globally drives the expansion and elevation of NBCUniversal’s iconic collection of brands, intellectual properties, characters, and stories based on the company’s extensive portfolio of properties created by Universal Pictures, Illumination, DreamWorks Animation and NBCUniversal Television and Streaming. The division executes this through innovative physical and digital products, as well as engaging retail and product experiences across our expansive global theme park destinations (for both owned and third-party IP), location-based venues, e-commerce product platforms, and retailers around the world. Along with global brand strategy and creative, UP&E’s lines of business include Consumer Products and Games, along with Theme Parks Products & Retail. UP&E is a division of Universal Destinations & Experiences, part of NBCUniversal, a subsidiary of Comcast Corporation. More information is available at universalproductsexperiences.com.

DreamWorks Kung Fu Panda © 2025 DreamWorks Animation LLC. All Rights Reserved 

Media Contact:
Gravity Interactive, Inc
biz@warpportal.com

ⓒ 2025 Gravity Co., Ltd.

DreamWorks Kung Fu Panda © 2025 DreamWorks Animation LLC. All Rights Reserved

Z.ai Unveils New GLM Open-Source Models with World-Class Reasoning Performance

BEIJING, April 16, 2025 /PRNewswire/ — Z.ai (formerly Zhipu) announces the open-sourcing of its 32B and 9B GLM model series, including base, reasoning, and rumination models, all under the MIT license. These models are now available for free access via the new z.ai website. This platform currently features the 32B base, reasoning, and rumination GLM models and will serve as the primary portal for interacting with and experiencing Z.ai’s latest model releases.

Model Open Source

All models in this open-source release are available under the MIT license. This allows for free commercial use and redistribution, granting developers significant flexibility in usage and development. The release includes models in two sizes, 9B and 32B, encompassing base, reasoning, and rumination models.

The GLM-4-32B-0414 base model, with 32 billion parameters, delivers performance competitive with larger mainstream models globally. Pre-trained on 15 Terabytes (TB) of high-quality data, including extensive synthetic data focused on reasoning, it lays a foundation for future reinforcement learning applications. In the post-training phase, beyond human preference alignment for dialogue scenarios, techniques like rejection sampling and reinforcement learning were employed to specifically enhance performance in instruction following, engineering code generation, and function calls, thereby bolstering the fundamental abilities required for agentic tasks. GLM-4-32B-0414 excels in engineering code generation, Artifacts creation, function calls, search-based question answering, and report writing, with some benchmark scores approaching or exceeding those of larger models like GPT-4o and DeepSeek-V3-0324 (671B).

GLM-4-32B-0414 has further improved code generation capabilities, capable of handling and generating more complex single-file code. Z.ai’s dialogue mode includes a preview feature, supporting visualization of generated HTML and SVG, facilitating user evaluation of results and iterative optimization.

GLM-Z1-32B-0414 is a reasoning model featuring advanced reasoning capabilities. Built upon GLM-4-32B-0414, it utilizes cold-start and extended reinforcement learning strategies and has undergone deep optimization training focused on key areas like mathematics, coding, and logic. Compared to the base model, GLM-Z1-32B-0414 shows significant enhancements in mathematical reasoning and complex problem-solving capabilities. Furthermore, the training integrated general reinforcement learning techniques leveraging pairwise critic rewards, effectively boosting the model’s overall general-purpose abilities.

In certain tasks, GLM-Z1-32B-0414, with its 32 billion parameters, matches the performance of DeepSeek-R1, which has 671 billion parameters. Through evaluations in benchmark tests such as AIME 24/25, LiveCodeBench, and GPQA, GLM-Z1-32B-0414 has demonstrated strong mathematical reasoning abilities, enabling it to address a broader range of complex tasks.

The GLM-Z1-9B-0414, a 9B model, delivers impressive performance for its size. Trained using the same advanced techniques applied to larger models, this smaller variant demonstrates excellent capabilities in mathematical reasoning and general tasks despite its reduced parameter count, ranking it among the leading open-source models in its size class. Particularly for resource-constrained environments, it strikes an effective balance between capability and efficiency, offering a strong option for users requiring lightweight deployment.

The rumination model GLM-Z1-Rumination-32B-0414 represents Z.ai’s next step in exploring the future form of AGI.

Unlike standard reasoning models, the Rumination model tackles highly open-ended and complex problems via a more extended, multi-step deliberation process. A key innovation is its ability to integrate search tools during this process to address complex tasks, guided by various rule-based reward mechanisms that steer and enhance end-to-end reinforcement learning. The model supports a full research cycle—autonomously formulating questions, searching for information, constructing analyses, and completing tasks—significantly boosting its proficiency in research-oriented writing and complex information retrieval.

Z.ai Launched

The new z.ai website, serving as the primary portal for interacting with Z.ai’s latest models, is now live!

Z.ai currently features three open-source models for interactive use:

  • GLM-4-32B (Base Model): Features powerful code generation capabilities, supports the new Artifacts feature, and enables an interactive development experience.
  • Z1-32B (Reasoning Model): Delivers superb reasoning performance, allowing users to experience inference speeds up to 200 Tokens/second online.
  • Z1-Rumination-32B (Rumination Model): Allows users to explore the powerful “Deep Research” capabilities, ideal for conducting in-depth investigations.

About Z.ai

Founded in 2019, Beijing Zhipu Huazhang Technology Co., Ltd. (Z.ai, formerly Zhipu) is a leading Chinese AI company focused on developing next-generation cognitive models. Since launching the GLM pre-training framework in 2020, Z.ai has released several industry-leading models, including GLM-130B and ChatGLM, with over 30 million global downloads. Its product suite includes QingYan, CodeGeeX, CogVLM, and CogView, as well as an innovative Model-as-a-Service (MaaS) platform for developers and enterprises. Recognized with numerous industry awards, Z.ai is driving progress towards the era of artificial general intelligence.

For more information, visit zhipuai.cn/en/.

Driving the Future of EASE Urban Mobility: The First-Ever SOUEAST Global EASE DAY to Launch in Shanghai

SHANGHAI, April 16, 2025 /PRNewswire/ — SOUEAST Motor is set to kick off the inaugural SOUEAST Global EASE DAY 2025 on April 21st in Shanghai, China. This global event will bring together international media and notable influencers for a five-day immersive experience, advancing the brand’s vision for EASE urban mobility through collaboration.

(Image: SOUEAST Global EASE DAY 2025)
(Image: SOUEAST Global EASE DAY 2025)

EASE DAY, SOUEAST’s first-ever global brand summit, will gather influential voices to forge meaningful media connection and amplify brand resonance. Serving dual purposes as both a milestone moment and a symbolic launchpad, this event will promote the brand’s transformation into a globally competitive auto force. Over the course of the event, guests will participate in a range of themed activities designed to foster deeper engagement.

The agenda features four core highlights: EASE Talk, EASE Experience, EASE Innovation, and EASE City. Through in-depth brand dialogues, test drives, car preview and urban cultural experiences, global media and notable influencers will gain a close-up understanding of SOUEAST’s brand vision and philosophy.

EASE YOUR LIFE in Motion

Since its comprehensive brand refresh in 2024, SOUEAST has rapidly expanded its international footprint, with successful rollouts across the Middle East and Central Asia. Guided by the brand philosophy, “EASE YOUR LIFE,” SOUEAST is reshaping urban mobility by combining global insight with local adaptation—offering customers stylish, comfort, and warm-tech driving experiences tailored to everyday city life.

EASE DAY 2025 represents a natural next step. The event will offer a platform for SOUEAST to engage closely with media through interactive experiences and strategic discussions. And attendees will gain firsthand insight into SOUEAST´s interpretation of intelligent urban mobility.

A Global Journey Begins in Shanghai

The first stop on the EASE DAY journey, Shanghai sets the tone for what SOUEAST envisions as a yearly tradition—bringing the global media and notable influencers together in a different symbolic city. By building a space for co-creation, shared insight, and cultural resonance, EASE DAY will bring extraordinary experiences to urban life.

Wanglaoji Launches WALOVI English Brand Identity in Kuala Lumpur to Strategically Expand in Malaysian Market

GUANGZHOU, China, April 15, 2025 /PRNewswire/ — Recently, Wanglaoji Great Health Industry Co.Ltd. (hereinafter referred to as “Wanglaoji”), a leading Chinese natural herbal beverage enterprise, accelerated its Southeast Asian market expansion by signing an agreement with the partner in Kuala Lumpur, Malaysia, to deepen market cooperation. Wanglaoji unveiled its English brand identity, WALOVI, and inked an international strategic partnership agreement with Baosteel Packaging Co., Ltd. (hereinafter referred to as “Baosteel Packaging”) in Kuala Selangor, Malaysia, marking the initial steps in building its overseas supply chain network.

Malaysia is China’s second-largest trading partner among ASEAN member states, while China has maintained its position as Malaysia’s largest trading partner for 16 consecutive years. With the deepening implementation of the Regional Comprehensive Economic Partnership (RCEP), this year, which coinciding with the 15th anniversary of the China – ASEAN Free Trade Area (CAFTA), has seen robust momentum injected into bilateral trade. Leveraging the tariff reduction policies under CAFTA 3.0, Chinese companies like Wanglaoji can now access Southeast Asian markets more efficiently.

On the morning of April 12, Wanglaoji and Baosteel Packaging signed a strategic cooperation agreement at Baosteel’s Can-Manufacturing Factory in Kuala Selangor. The two parties conducted in-depth cooperation in three aspects: overseas supply chain synergy, international market expansion, and packaging innovation R&D. This powerhouse alliance aims to enhance brand influence overseas and deliver superior products to consumers worldwide.

Wanglaoji herbal drink, which is renowned in China for its natural herbal formula with the function of preventing excessive “internal heat”, is now available in over 100 countries and regions worldwide. Baosteel Packaging, a leader in metal packaging materials for China’s fast-moving consumer goods sector, has established production lines in Vietnam, Malaysia, and other regions since 2012, boasting efficient localized production capabilities and flexible supply chains. Having been collaborating domestically for over a decade, the two companies are now elevating their partnership to the global strategic level.

Later that afternoon, Wanglaoji hosted the WALOVI English brand launch ceremony in Kuala Lumpur and signed a strategic market – expansion cooperation agreement with Baida International Trading Sdn. Bhd., a prominent “Southeast Asian service provider for Chinese brands expanding overseas”. Both parties agreed to strengthen sales and marketing efforts in Malaysia, jointly pursuing greater business growth. Moving forward, the WALOVI products will enter the Malaysian market through diversified channels, which cover mainstream retail outlets and consumer scenarios.

Fang Dafeng, General Manager of Wanglaoji, stated that Malaysia serves not only as a key stronghold for Wanglaoji’s brand-promotion in Southeast Asia but also as a pivotal hub in its globalization strategy. “We developed the PCBC Global Value Model—focusing on ‘Product, Channel, Brand, and Culture’—to tailor product for overseas markets, establish localized channel networks, promote the WALOVI English brand, and foster cultural integration. By championing Chinese health philosophy, we aim to elevate Wanglaoji into a global super beverage brand,” he emphasized.